Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ustekinumab - Janssen Biotech

Drug Profile

Ustekinumab - Janssen Biotech

Alternative Names: Anti-interleukin-12 p40 monoclonal antibody; CNTO-1275; STELARA; Stelara; Stellara; Sterrara; Suterara

Latest Information Update: 18 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centocor; Medarex
  • Developer Centocor; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Plaque psoriasis; Psoriatic arthritis
  • Registered Ulcerative colitis
  • Phase III Dermatomyositis; Polymyositis; Spondylarthritis; Systemic lupus erythematosus
  • Phase II Atopic dermatitis
  • Discontinued Multiple sclerosis; Palmoplantar pustulosis; Primary biliary cirrhosis; Rheumatoid arthritis; Sarcoidosis

Most Recent Events

  • 21 Oct 2019 Registered for Ulcerative colitis (Treatment-experienced) in USA (SC)
  • 21 Oct 2019 Registered for Ulcerative colitis (Treatment-experienced) in USA (IV)
  • 21 Oct 2019 Long term adverse events and efficacy data from the phase III UNIFI trial in Ulcerative colitis released by Janssen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top